Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Hepatocellular 3Sarcoma, Ewing 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1

Interventions

Temozolomide 2tazemetostat 1talazoparib 1irinotecan sucrosofate 1etoposide phosphate 1dinutuximab 1atezolizumab 1abemaciclib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Phantoms, Imaging 1Nivolumab 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Eflornithine 1Dasatinib 1Carboplatin 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdoid Tumor × X-Rays × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡